Eli Lilly’s Strategic Gambit: A Price War for Market Supremacy

Pharmaceutical titan Eli Lilly has launched an aggressive offensive in the lucrative weight-loss drug sector, initiating a price war that directly challenges rival Novo Nordisk. In a bold strategic shift away from margin protection, the company has announced deep cuts to the list price of its blockbuster drug, Zepbound. This move raises a pivotal question: is this a masterstroke to secure total market dominance, or a perilous gamble with profitability?

The initial investor reaction to potential margin compression was short-lived, giving way to notable optimism from major financial institutions. Several leading investment banks revised their price targets upward following Tuesday’s announcement.

• Analysts at Bank Read more...